SCHEMBL6091489

SCHEMBL6091489

COC(=O)c1ccc(C(=O)Cc2cc(-c3ccsc3)ccc2OC)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 1/20 0.43
HDAC2 Q92769 1/20 0.43
NR4A2 P43354 1/20 0.43
TUBB4A P04350 1/20 0.42
TUBB P07437 1/20 0.42
TUBA3C P0DPH7 1/20 0.42
TUBA1B P68363 1/20 0.42
TUBA4A P68366 1/20 0.42
TUBB4B P68371 1/20 0.42
TUBB3 Q13509 1/20 0.42
TUBB2A Q13885 1/20 0.42
TUBB8 Q3ZCM7 1/20 0.42
TUBA3E Q6PEY2 1/20 0.42
TUBA1A Q71U36 1/20 0.42
TUBA1C Q9BQE3 1/20 0.42
TUBB6 Q9BUF5 1/20 0.42
TUBB2B Q9BVA1 1/20 0.42
TUBB1 Q9H4B7 1/20 0.42
MAPT P10636 4/20 0.41
KMT2A Q03164 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6091799 0.89 CHEK2 (0.43) HDAC1HDAC2TUBB4ATUBBTUBA3C
SCHEMBL6092548 0.81 KDM4E (0.50) HDAC1HDAC2NR4A2MAPTKMT2A
SCHEMBL6091795 0.77 CYP19A1 (0.59) NR4A2KMT2AMEN1KDM4E
SCHEMBL6094331 0.76 KMT2A (0.49) MAPTKMT2AMEN1CYP1A2CYP3A4
SCHEMBL4685840 0.76 NR4A2 (0.61) HDAC1HDAC2NR4A2TUBB4ATUBB
SCHEMBL6092134 0.75 TNFRSF1A (0.52) HDAC2MAPTKMT2AMEN1HIF1A
SCHEMBL6092281 0.74 ALPL (0.50) MAPTKMT2AMEN1SMN1; SMN2NPC1
SCHEMBL3628928 0.72 NR4A2 (0.53) HDAC1NR4A2TUBB4ATUBBTUBA3C
SCHEMBL6092689 0.70 MAPT (0.45) HDAC1HDAC2NR4A2MAPTKMT2A
SCHEMBL1697936 0.70 CA12 (0.54) NR4A2ERN1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060063828-A1 1,2-Bis-(substituted-phenyl)-2-propen-1-ones and pharmaceutical compositions thereof ATHEROGENICS, INC. 2006-03-23 US disclosed
WO-2006004903-A2 1,2-BIS-(SUBSTITUTED-PHENYL)-2-PROPEN-1-ONES AND PHARMACEUTICAL COMPOSITIONS THEREOF ATHEROGENICS, INC. (US) 2006-01-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060063828-A1 1,2-Bis-(substituted-phenyl)-2-propen-1-ones and pharmaceutical compositions thereof ABCB11, CEL, CYP46A1 HDAC1 1097/4885HDAC2 651/4885NR4A2 3759/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.